Psychedelics biotech Tryp Therapeutics TRYPF is progressing its psilocybin-based portfolio through recent milestones. The Upcoming Phase 1 Trial For IV Psilocin Initially, the company received ...

Morgan Stanley has identified several stocks they consider top picks for 2024. Here’s a summary of what the firm’s top stock picks are and what ...

The Current State of Semiconductor Supply in the Automotive Industry The automotive end market is experiencing a slowdown, as semiconductor content rises in vehicles but ...

The American corporate landscape is facing a dire dilemma as empty office spaces across the United States hit their highest vacancy rates since 1979, according ...

The Palantir Perspective The rise of Palantir Technologies (PLTR) in 2023 as an AI-centric growth stock has been a roller coaster of excitement and skepticism. ...

The Anticipated Approval This week, the SEC is expected to give their decision on a proposed spot bitcoin ETF and, according to some analysts, approval ...

Dada Nexus Grapples with Revenue Missteps The Shock and the Fall JD.com unit Dada Nexus (NASDAQ:DADA) experienced a stunning 26% premarket plunge when the company ...

As the market for income-oriented stocks continues to evolve, investors are frequently on the lookout for options with robust potential. On January 8th, three stocks ...

Apple (NASDAQ: AAPL) stock saw a 47% rise in 2023, but the beginning of 2024 has been less forgiving, marking a 4% downturn. Reasoning behind ...

Ibogaine Therapy Reveals Promise for Trauma Brain Injury A first-in-class clinical trial on ibogaine-magnesium therapy for Special Operations Veterans (SOV) with repeated blast exposure, published ...